MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
Adoptive immunotherapy using cytokine-induced killer (CIK) cells is a promising cancer treatment, but its efficacy is restricted by various factors, including the accumulation of myeloid-derived suppressor cells (MDSCs). In this study, we determine whether chemotherapeutic drugs that reduce MDSC levels enhance the efficacy of CIK cell therapy in the treatment of solid tumors. Fifty-three patients were included in this study; 17 were diagnosed with metastatic renal cell carcinoma (MRCC), 10 with advanced pancreatic cancer (PC), and 26 with metastatic melanoma (MM). These patients were divided into two groups: CIK cell therapy alone and CIK cell therapy combined with chemotherapy. Combining CIK cell therapy and chemotherapy increased 1-year survival rates and median survival times in MRCC and PC patients, but not in MM patients. The disease control rate did not differ between treatment groups for MRCC or MM patients, but was higher in PC patients receiving combined treatment than CIK cell treatment alone. These data suggest that addition of MDSC-decreasing chemotherapy to CIK cell therapy improves survival in MRCC and PC patients.
['Wang|Zibing|Z|', 'Liu|Yuqing|Y|', 'Zhang|Yong|Y|', 'Shang|Yiman|Y|', 'Gao|Quanli|Q|']
D000328:Adult D000368:Aged D000971:Antineoplastic Combined Chemotherapy Protocols D014408:Biomarkers, Tumor D002292:Carcinoma, Renal Cell D015331:Cohort Studies D003131:Combined Modality Therapy D055612:Cytokine-Induced Killer Cells D005260:Female D005500:Follow-Up Studies D006801:Humans D007167:Immunotherapy D007680:Kidney Neoplasms D008297:Male D008875:Middle Aged D022423:Myeloid Cells D009367:Neoplasm Staging D010190:Pancreatic Neoplasms D011379:Prognosis D015996:Survival Rate D055815:Young Adult
cytokine-induced killer cells immunotherapy myeloid-derived suppressor cells solid tumors overall survival